Cargando…

Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells

Myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) represent prominent components in cancer progression. We previously showed that inhibition of the VEGFR-3 pathway by SAR131675 leads to reduction of TAM infiltration and tumor growth. Here, we found that treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espagnolle, Nicolas, Barron, Pauline, Mandron, Marie, Blanc, Isabelle, Bonnin, Jacques, Agnel, Magali, Kerbelec, Erwan, Herault, Jean Pascal, Savi, Pierre, Bono, Françoise, Alam, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980599/ https://www.ncbi.nlm.nih.gov/pubmed/24589997 http://dx.doi.org/10.3390/cancers6010472

Ejemplares similares

Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice
por: Hwang, Seun Deuk, et al.
Publicado: (2019)

SAR131675, a VEGRF3 Inhibitor, Modulates the Immune Response and Reduces the Growth of Colorectal Cancer Liver Metastasis
por: Walsh, Katrina A., et al.
Publicado: (2022)

Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy
por: Paillasse, Michael R., et al.
Publicado: (2022)

VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
por: Amano, Hideki, et al.
Publicado: (2021)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

CD54-Mediated Interaction with Pro-inflammatory Macrophages Increases the Immunosuppressive Function of Human Mesenchymal Stromal Cells
por: Espagnolle, Nicolas, et al.
Publicado: (2017)

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
por: Bhargava, Pankaj, et al.
Publicado: (2011)

Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression
por: Liu, Tingting, et al.
Publicado: (2019)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

Integrin β(3) Crosstalk with VEGFR Accommodating Tyrosine Phosphorylation as a Regulatory Switch
por: West, Xiaoxia Z., et al.
Publicado: (2012)

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma
por: Kinget, Lisa, et al.
Publicado: (2021)

Elements of the Endomucin Extracellular Domain Essential for VEGF-Induced VEGFR2 Activity
por: Hu, Zhengping, et al.
Publicado: (2020)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
por: Arena, Claudia, et al.
Publicado: (2018)

PRMT4-mediated arginine methylation promotes tyrosine phosphorylation of VEGFR-2 and regulates filopodia protrusions
por: Hartsough, Edward, et al.
Publicado: (2022)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer
por: D’Haene, Nicky, et al.
Publicado: (2018)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis
por: Stevens, Megan, et al.
Publicado: (2019)

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013)

Endosome-to-Plasma Membrane Recycling of VEGFR2 Receptor Tyrosine Kinase Regulates Endothelial Function and Blood Vessel Formation
por: Jopling, Helen M., et al.
Publicado: (2014)

Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors
por: Xu, Yingzhuo, et al.
Publicado: (2022)

Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
por: Zhang, Ninggang, et al.
Publicado: (2022)

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
por: Hsu, Jeff, et al.
Publicado: (2023)

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
por: Zhao, Tong T., et al.
Publicado: (2010)

Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Publicado: (2019)

Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2
por: Sangande, Frangky, et al.
Publicado: (2020)

Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells
por: Hwang, Jun-Eul, et al.
Publicado: (2013)

Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation
por: Dieterich, Lothar C., et al.
Publicado: (2017)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

Extraperitoneal laparoscopic radical prostatectomy: A prospective 2-year single-surgeon experience with 171 cases
por: Leitão, Tito Palmela, et al.
Publicado: (2012)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles
por: Abdel-Mohsen, Heba T., et al.
Publicado: (2020)

Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
por: Altamimi, Abdulmalik S., et al.
Publicado: (2021)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
por: Jinnin, Masatoshi, et al.
Publicado: (2008)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects
por: Chang, Yi-Wen, et al.
Publicado: (2014)

VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis
por: D'Haene, Nicky, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fufnua88b041vatmmudd7i5pdp